Study identifier:NIS-OAR-XXX-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.
Stage IIIB/IV
-
No
-
All
450
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2014 by AstraZeneca
AstraZeneca
-
The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.
Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.
Location
Location
Ciudad de Buenos Aires, Buenos Aires, Argentina
Location
San Luis, San Luis, Argentina
Location
Santa Fe, SANTA FE, Argentina
Location
Rosario, SANTA FE, Argentina
Location
La Plata, Buenos Aires, Argentina
Location
Mar del Plata, Buenos Aires, Argentina
Location
Bahia Blanca, Buenos Aires, Argentina
Location
Cordoba, Cordoba, Argentina
Arms | Assigned Interventions |
---|---|
Case | - |
Control | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.